RATIONALE: Up to 40% of patients with angioedema without urticaria have no identifiable trigger. Previous studies have found that 80% of these patients can be classified as histaminergic based on clinical response to H1 antihistamines. Therefore, we sought to analyze changes in frequency of episodes after starting daily antihistamine therapy in patients previously identified with recurrent idiopathic angioedema. METHODS: We examined a cohort of patients previously diagnosed with idiopathic angioedema and seen at a University of Wisconsin Allergy clinic. Patients who had recurrent episodes of angioedema at baseline and were subsequently started on daily H1 antihistamine therapy were identified. Data collected included demographics and frequency of symptoms both at baseline and at last contact with a healthcare provider. RESULTS: Of 157 patients with idiopathic angioedema, 82 were started on daily long-acting H1 antihistamines. 68 of these patients had recurrent episodes prior to starting therapy. Frequency of episodes at baseline was daily (16%), weekly (15%), monthly (49%), greater than once yearly (16%) and once yearly (4%). For patients not lost to follow-up, frequency decreased to 0% daily, 2% weekly, 4% monthly, 6% greater than once yearly, and 12% once yearly. 44% of patients had no episodes at this time. Overall 48 patients (63%) had an absolute decrease in frequency of episodes (p < 0.001). CONCLUSIONS: A significant portion of patients with idiopathic angioedema can be classified as histaminergic based on response to antihistamine therapy. Daily long-acting antihistamines can be effective in reducing the frequency of angioedema episodes. RATIONALE: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disorder with a great genetic complexity. More than 400 mutations related to its pathogenesis have been published. We analyzed the mutational spectrum of the SERPING1 gene in our pediatric population with C1-INH-HAE. METHODS: We prospectively studied 13 children from 12 unrelated families with laboratory and/ or clinical diagnosis of C1-INH-HAE. At the time of the study, children were age 1 to 18 years (53.85% males). DNA samples were collected from peripheral blood and all eight exons and adjacent intronic regions of SERPING1 gene were sequenced following standard protocols. RESULTS: A total of 12 different mutations were identified ( two of the children were siblings). We observed a great variability, the mutations comprised 4 frameshift mutations, 3 nonsense mutations, 3 missense mutations and 1 mutation affecting the splicing sites. Only one large insertion of SERPING 1 gene was detected. Few of the detected mutations were novel and not published previously, including a novel mutation affecting the second intronic region. No correlation between genotype and clinical expression was observed. CONCLUSIONS: In our pediatric C1-INH-HAE population we corroborate the great allelic heterogeneity with each individual carrying their own mutation. Conversely, progesterone may decrease attack frequency. The mechanism by which estrogen exacerbates HAE-C1-INH is not well characterized. METHODS: To evaluate whether oral contraceptives (OCPs) containing >20mg estrogen alter plasma protein levels of bradykinin (BK), and its precursor, high-molecular-weight kininogen (HMWK), plasma was collected prior to, and 3-months after initiation of OCPs. Protein HMWK and BK were measured by ELISA. As estrogen use is contraindicated for patients with HAE-C1-INH, females without a history consistent with HAE and with a normal C4 were recruited. RESULTS: Nine adult females (<40 years of age) had median baseline HMWK of 33,411,500 pg/ml [IQR: 23,690,076,250] and BK of 6,756 pg/ml [IQR: 2,652.5]. After 3 months of OCP therapy, the median HMWK increased to 36,386,500 pg/ml [IQR: 34,587,506,500] and BK to 7,980 pg/ml [IQR: 3,206.2]. These values corresponded to a mean fold increase of 0.94 (HMWK) and 0.83 (BK). CONCLUSIONS: This preliminary study, performed in females without HAE, suggests that estrogen may exacerbate angioedema by increasing the production of HMWK and BK, an important mediator of HAE-C1-INH. Additional work is needed to address the effects of estrogen on BK degradation and expression of the bradykinin B2-receptor. results from a deficiency of C1 esterase inhibitor, causing uncontrolled plasma kallikrein activity and excess production of bradykinin, a regulator of blood pressure. Lanadelumab specifically targets active plasma kallikrein, and was efficacious in the prevention of HAE attacks in the phase 3 HELP Study (NCT02586805). We examined the effect of lanadelumab-associated reductions in kallikrein activity on blood pressure. METHODS: Patients > _12 years with type I/II HAE and > _1 attack during a 4-week run-in received SC lanadelumab 300mg q2wks, 300mg q4wks, 150mg q4wks, or placebo over 26 weeks. Angiotensin-converting enzyme (ACE) inhibitor use was not permitted during the study period. RESULTS: 125 patients received > _1 dose of study medication (lanadelumab, n584; placebo, n541) and were included in the safety analyses. Of these, 78 [92.8%] and 35 [85.4%] patients in lanadelumab and placebo arms completed the study. At baseline, 18 (14.4%) patients had a history of hypertension, 6 (14.6%) in the placebo arm and 12 (14.3%) in lanadelumab arms. Blood pressure remained stable over time with lanadelumab, while diastolic blood pressure slightly decreased over time with placebo (change from baseline to day 182: -3.17 mmHg vs 1.34 mmHg with lanadelumab, p50.002). There was no increased use of anti-hypertensive medication with lanadelumab vs placebo. One patient receiving lanadelumab 150mg q4wks reported a treatment-emergent adverse event (TEAE) of increased blood pressure to 124/91 mmHg. No clinically significant ECG abnormalities were observed. CONCLUSIONS: These data suggest there is no increased risk of hypertension or ECG abnormalities with lanadelumab vs placebo in patients with HAE.
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